Inclusion Criteria:  Newly-diagnosed acute myeloid leukemia (AML) and eligible to receive venetoclax as per local label. Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.  Exclusion Criteria:  Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.